Although the Central Illinois CCOP is only in its third year of funded operation, we have already achieved several of our initial aims, including: establishing a functional consortium of leading institutions in Central Illinois, dedicated to a cancer care system and committed to providing resources to assure its success and stability; maintaining a joint cancer data system that consolidates registry and patterns of care information from the participating institutions; and solidifying cancer research resources, centralizing data management support to clinical investigators at participating hospitals. The achievement of these initial aims has allowed us to initiate a series of new aims: to develop and implement a program of cancer control research that assures the CCOP will meet and exceed NCI requirements for cancer control accrual; to involve cancer specialists from participating institutions in a variety of activities that provide a common experience and strengthen each of the participating institutions; to set a pace for protocol accrual that meets and exceeds the standard for comparable CCOPs; to maintain quality control procedures, physician participation policies, pharmaceutical policies and protocol selection policies at the highest possible levels. Several important features of the CICCOP have made it possible for the organization to quickly become a preeminent member of the CCOP network. The principal investigator has demonstrated remarkable leadership ability, which enabled CICCOP to rapidly implement a strong multi-institutional research program that has both exceptional levels of quality control and solid accruals. We have demonstrated a significant ability to accrue patients to therapeutic clinical trials and in Year Two of NCI funding accrued 105 patients to clinical trials while still maintaining quality data collection. CICCOP's ability to accrue patients to cancer control protocols is also outstanding, and we have accrued 88 patients to cancer control protocols this year. High levels of community financial support have also contributed to our success. Our high standards of achievement have been recognized by our research bases, and CICCOP is considered to be a """"""""superior performer"""""""". Central Illinois Community Clinical Oncology Program offers the NCI a unique history of past performance and a promise of continued achievements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045807-08
Application #
3558707
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-08-15
Project End
1995-05-31
Budget Start
1993-06-01
Budget End
1994-05-31
Support Year
8
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Decatur Memorial Hospital
Department
Type
DUNS #
046584991
City
Decatur
State
IL
Country
United States
Zip Code
62526
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 59 publications